ArticleCurrent treatment options in allergy2025
Innovations and Emerging Therapies in Atopic Dermatitis Part 1.
Article in Current treatment options in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Purpose of Review: The purpose of this review is to discuss the innovative aspects of present and newer therapies used for the treatment of AD, as well as to highlight the characteristics of emerging treatments. We also compare alternative systemic therapies. The novelties surrounding systemic therapies will be highlighted in this first review (part 1), while innovations in topical therapies will be discussed in a subsequent review (part 2). Recent Findings: The treatment landscape of atopic dermatitis has been quickly evolving in recent history. The treatment framework of AD is shifting from broad suppression of the inflammatory response to targeted molecular therapy. Summary: Overall, this therapeutic shift does appear to correlate with a superior efficacy and safety profile, though we also highlight encountered shortcomings when assessing long-term and real-world data of systemic therapies. Despite significant recent advances, future studies are needed to optimize formulations and performance of systemic therapies for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.